Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 14/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 12/20 | 1.00 |
| ▸ | CYP17A1 | P05093 | 1/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | POLB | P06746 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.79 |
| ▸ | QPCT | Q16769 | 1/20 | 0.79 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.79 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.79 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.66 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2529997 | 0.93 | CYP11B1 (0.86) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| Benzylimidazole SCHEMBL414 | 0.89 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| SCHEMBL22063900 | 0.89 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| Benzylimidazole SCHEMBL29239318 | 0.87 | CYP11B1 (0.96) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| Benzylimidazole SCHEMBL16237308 | 0.87 | CYP11B1 (0.96) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| Benzylimidazole SCHEMBL31453527 | 0.87 | CYP11B1 (0.96) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| Benzylimidazole SCHEMBL3786782 | 0.87 | CYP11B1 (0.96) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| Benzylimidazole SCHEMBL411827 | 0.87 | CYP11B1 (0.96) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| SCHEMBL1024261 | 0.87 | CYP11B1 (0.84) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 | |
| Benzylimidazole SCHEMBL27535101 | 0.86 | CYP11B1 (0.86) | CYP11B1CYP11B2CYP17A1CYP19A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264753-A1 | NOVEL 1-(BIPHENYL-4-YL-METHYL)-1H-IMIDAZOLE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2012-10-18 | — | — | US | claimed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20120264753-A1 | NOVEL 1-(BIPHENYL-4-YL-METHYL)-1H-IMIDAZOLE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120264753-A1 | NOVEL 1-(BIPHENYL-4-YL-METHYL)-1H-IMIDAZOLE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2012-10-18 | — | — | US | disclosed |
| WO-2011077712-A1 | NOVEL 1-(BIPHENYL-4-YL-METHYL)-1H-IMIDAZOLE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | 興和株式会社 (JP) | 2011-06-30 | — | — | WO | disclosed |
| US-20100304998-A1 | Chemical Proteomic Assay for Optimizing Drug Binding to Target Proteins | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100304998-A1 | Chemical Proteomic Assay for Optimizing Drug Binding to Target Proteins | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| CN-100453117-C | Pharmaceutical compositions comprising selective I1 imidazoline receptor agonists and angiotensin II receptor blockers | SOLVAY PHARM GMBH (DE) | 2009-01-21 | — | — | CN | disclosed |
| CN-1859924-A | Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker | SOLVAY PHARM GMBH (DE) | 2006-11-08 | — | — | CN | disclosed |
| US-20060167269-A1 | Compounds and methods for the inhibition of compounds cruzi | NATIONAL INSTITUTES OF HEALTH | 2006-07-27 | — | — | US | disclosed |
| WO-2003006012-A1 | COMPOUNDS AND METHODS FOR THE INHIBITION OF TRYPANOSOMA CRUZ I | YALE UNIVERSITY (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167269-A1 | Compounds and methods for the inhibition of compounds cruzi | CBR3, CBR1, C1R | CYP11B1 207/4885CYP11B2 320/4885CYP17A1 1868/4885 |
| US-20120264753-A1 | NOVEL 1-(BIPHENYL-4-YL-METHYL)-1H-IMIDAZOLE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | PPARG, PPARD, PPARA | CYP11B1 95/4885CYP11B2 152/4885CYP17A1 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.